Left Arrow IconPreviousRight Arrow IconNextPlus IconExpandMinus IconCollapseMagnifying Glass IconSearch

WebView

YearNumberLinkReferenceTitleAuthors
Hide details for Published in 2015Published in 2015
207ClickN Engl J Med. 2015 Dec 24;373(26):2534-48.Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing SpondylitisBaeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB; MEASURE 1 Study Group; MEASURE 2 Study Group
206ClickMedicina (Kaunas) 2015;51(1):25-31.Predictors of mortality in patients with rheumatoid arthritis in Lithuania: Data from a cohort study over 10 years.Dadonienė J, Stropuvienė S, Stukas R, Venalis A, Sokka-Isler T.
205ClickExpert Opin Biol Ther. 2015 15(12):1677-83Cost-Effectiveness of Biologics Compared to Conventional Disease-Modifying Antirheumatic Drugs for Treatment of Rheumatoid Arthritis in Finland.Joensuu JT, Aaltonen KJ, Aronen P, Sokka T, Puolakka K, Tuompo R, Korpela M, Vasala M, Ilva K, Nordström D, Blom M.
204ClickExpert Opin Biol Ther. 2015 Nov 7:1-7. [Epub ahead of print]Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data.Nikiphorou E, Kautiainen H, Hannonen P, Asikainen J, Kokko A, Rannio T, Sokka T.
203ClickJ Rheumatol. 2015 Sep;42(9):1542-4.Rheumatoid Arthritis in the 21st Century: Treatment Patterns and Disease Activity States.Nikiphorou E, Rannio T, Sokka T.
202ClickArthritis Res Ther. 2015 Aug 20;17(1):219Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern NorwayHaugeberg G, Hansen IJ, Soldal DM, Sokka T.
201ClickArthritis Res Ther. 2015 May 9;17:117. doi: 10.1186/s13075-015-0646-xUtility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosisOrmseth MJ, Chung CP, Oeser AM, Connelly MA, Sokka T, Raggi P, Solus JF, Otvos JD, Stein CM.
200ClickPLoS One 2015 Apr 8;10(4):e0123582. doi: 10.1371/journal.pone.0123582. eCollection 2015A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritisMichelsen B, Fiane R, Diamantopoulos AP, Soldal DM, Hansen IJ, Sokka T, Kavanaugh A, Haugeberg G
199ClickJ Rheumatol. 2015 Mar;42(3):372-8. doi: 10.3899/jrheum.140853. Epub 2015 Jan 15.Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapyAaltonen KJ, Joensuu JT, Virkki L, Sokka T, Aronen P, Relas H, Valleala H, Rantalaiho V, Pirilä L, Puolakka K, Uusitalo T, Blom M, Konttinen YT, Nordström D.
198ClickNeuroimmunomodulation 2015;22(1-2):89-103. doi: 10.1159/000362735. Epub 2014 Sep 12The past versus the present, 1980-2004: reduction of mean initial low-dose, long-term glucocorticoid therapy in rheumatoid arthritis from 10.3 to 3.6 mg/day, concomitant with early methotrexate, with long-term effectiveness and safety of less than 5 mg/day.Pincus T, Sokka T, Cutolo M.
Show details for Published in 2014Published in 2014
Show details for Published in 2013Published in 2013
Show details for Published in 2012Published in 2012
Show details for Published in 2011Published in 2011
Show details for Published in 2010Published in 2010
Show details for Published in 2009Published in 2009
Show details for Published in 2008Published in 2008
Show details for Published in 2007Published in 2007
Left Arrow IconPreviousRight Arrow IconNextPlus IconExpandMinus IconCollapseMagnifying Glass IconSearch